Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464921/
https://www.ncbi.nlm.nih.gov/pubmed/37433025
http://dx.doi.org/10.1093/ijnp/pyad038
_version_ 1785098569461530624
collection PubMed
description
format Online
Article
Text
id pubmed-10464921
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104649212023-08-30 Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone? Int J Neuropsychopharmacol Corrigendum Oxford University Press 2023-07-11 /pmc/articles/PMC10464921/ /pubmed/37433025 http://dx.doi.org/10.1093/ijnp/pyad038 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of CINP. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Corrigendum
Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title_full Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title_fullStr Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title_full_unstemmed Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title_short Corrigendum to: A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
title_sort corrigendum to: a study in first-episode psychosis patients: does angiotensin i-converting enzyme activity associated with genotype predict symptom severity reductions after treatment with atypical antipsychotic risperidone?
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464921/
https://www.ncbi.nlm.nih.gov/pubmed/37433025
http://dx.doi.org/10.1093/ijnp/pyad038

Ejemplares similares